---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-075050"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2022-06-28T23:59:59+00:00"
generated_at: "2026-06-24T22:40:07.614609+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Hepion appoints Anand Reddi and Kaouthar Lbiati to Board of Directors

## Summary
- Board expanded to 8; Reddi and Lbiati appointed independent directors effective June 27, 2022.
- Each receives $50,000 annual cash retainer and option to purchase 60,000 shares of common stock.
- Anand Reddi is VP at Adverum Biotechnologies; previously led international access at Gilead for HIV and hepatitis drugs.
- Kaouthar Lbiati is VP at Cytovia Therapeutics; held global leadership roles at Amgen, GSK, and Sanofi.
- Company is preparing rencofilstat for three Phase 2 trials in NASH and HCC and exploring partnering opportunities.

## SEC filing metadata
- accession: 0001104659-22-075050
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2022-06-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465922075050/0001104659-22-075050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465922075050/tm2219550d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-075050
- JSON: https://secwatch.observer/filing/0001104659-22-075050.json
- Plain text: https://secwatch.observer/filing/0001104659-22-075050.txt

## Key facts
- Executive change
  Kaouthar Lbiati was elected as independent director at Hepion Pharmaceuticals, Inc..
  - Action: elected
  - Role: independent director
  source text: the Board of Directors (the “Board”) of Hepion Pharmaceuticals, Inc. (the “Company”) increased the size of the Board to eight members and elected Anand Reddi, M.S. and Kaouthar Lbiati, M.D. as independent directors, effective June 27, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465922075050/0001104659-22-075050-index.htm
- Executive change
  Anand Reddi was elected as independent director at Hepion Pharmaceuticals, Inc..
  - Action: elected
  - Role: independent director
  source text: the Board of Directors (the “Board”) of Hepion Pharmaceuticals, Inc. (the “Company”) increased the size of the Board to eight members and elected Anand Reddi, M.S. and Kaouthar Lbiati, M.D. as independent directors, effective June 27, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000110465922075050/0001104659-22-075050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.